A randomized, double-blind, multicenter, phase II, three-arm, placebo-control study of apatinib as third-line treatment in patients with metastatic gastric carcinoma.

作者:Li, J.; Qin, S.; Xu, J.; Guo, W. J.; Xiong, J. P.; Bai, Y.; Sun, G.; Yang, Y.; Wang, L.; Xu, N.; Cheng, Y.; Zhe-Hai, W.; Zheng, L.; Tao, M.
DOI:10.1200/jco.2011.29.15_suppl.4019